No clear path forward emerged from the multitude of A-list regulators, stakeholders and legislators at the House Energy & Commerce Committee’s May 6 meeting on accelerating biomedical innovation – the multitude of solutions put forth made clear what a complex and cumbersome task a truly revolutionizing piece of legislation might need to be.
And despite being billed as a bipartisan effort with support of leadership on both sides of the aisle, the first signs of partisan and ideological
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?